Kopsavilkums
The synthesis and antiribosomal and antibacterial activity of both anomers of a novel apralog, 5-O-(5-amino-3-C-dimethylaminopropyl-D-ribofuranosyl)apramycin, are reported. Both anomers show excellent activity for the inhibition of bacterial ribosomes and that of MRSA and various wild-type Gram negative pathogens. The new compounds retain activity in the presence of the aminoglycoside phosphoryltransferase aminoglycoside modifying enzymes that act on the primary hydroxy group of typical 4,5-(2-deoxystreptamine)-type aminoglycoside and related apramycin derivatives. Unexpectedly, the two anomers have comparable activity both for the inhibition of bacterial ribosomes and of the various bacterial strains tested.
| Oriģinālvaloda | Angļu |
|---|---|
| Raksta numurs | 25 |
| Žurnāls | Antibiotics |
| Sējums | 12 |
| Izdevuma numurs | 1 |
| DOIs | |
| Publikācijas statuss | Publicēts - janv. 2023 |
| Ārēji publicēts | Jā |
ANO IAM
Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)
-
3. IAM — Laba Veselība un Labbūtība
Nospiedums
Uzziniet vairāk par pētniecības tēmām “Synthesis, Antibacterial and Antiribosomal Activity of the 3C-Aminoalkyl Modification in the Ribofuranosyl Ring of Apralogs (5-O-Ribofuranosyl Apramycins)”. Kopā tie veido unikālu nospiedumu.Citēt šo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver